SurModics, Inc. (SRDX)
| Market Cap | 800.44M |
| Revenue (ttm) | 94.55M |
| Net Income (ttm) | 701,000 |
| Shares Out | 13.67M |
| EPS (ttm) | 0.05 |
| PE Ratio | 1,163.80 |
| Forward PE | 161.29 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $58.19 |
| Previous Close | $59.15 |
| Change ($) | -0.96 |
| Change (%) | -1.62% |
| Day's Open | 59.71 |
| Day's Range | 57.65 - 60.00 |
| Day's Volume | 24,341 |
| 52-Week Range | 33.45 - 60.00 |
PAHC vs. SRDX: Which Stock Is the Better Value Option?
Let's take a look at the three MedTech stocks performing well lately, banking on a host of impressive developments.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Access--Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics to Present at Sidoti & Company Virtual Investor Conference Thursday, March 25, at 10:00 a.m. (ET)
Investor optimism is high on Surmodics (SRDX) stock, courtesy of its solid prospects.
Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.
SurModics (SRDX) delivered earnings and revenue surprises of 133.33% and -3.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Surmodics (NASDAQ:SRDX) rose 2.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 60.00% over the past year to $0.02, which beat the esti...
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports First Quarter Fiscal 2021 Results
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics to Host Virtual Annual Meeting of Shareholders on February 11 at 4:00 p.m. (CT)
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics to Webcast First Quarter Fiscal 2021 Earnings Conference Call on February 9.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #DCB--12-Month Data from Surmodics' TRANSCEND Trial Presented at LINC 2021. SurVeil™ Drug-Coated Balloon (DCB) demonstrates non-inferior safety and efficacy
PAHC vs. SRDX: Which Stock Is the Better Value Option?
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Announces TRANSCEND Trial 12-Month Data to be Presented at LINC 2021 Virtual Event.
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Avess--Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020; Study finds 100 percent target lesion patency at 30 days.
According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.
Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.
Surmodics, Inc.'s (SRDX) CEO Gary Maharaj on Q4 2020 Results - Earnings Call Transcript
SurModics (SRDX) delivered earnings and revenue surprises of -1900.00% and 4.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports Fourth Quarter Fiscal 2020 Results
Surmodics is in the early stages of an extended growth period in our view, with high conversion potential from their pipeline. The company has key differentiators within its medical devices and IVD segm...
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics, Inc. (Nasdaq: SRDX), to webcast Fourth quarter fiscal 2020 earnings in a conference call on November 4, 2020.
NUVA vs. SRDX: Which Stock Is the Better Value Option?
The FDA clearance of Surmodics' (SRDX) Pounce Thrombus Retrieval System will bolster the current treatment of complex PAD.
Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.
Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.
Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q3 2020 Results - Earnings Call Transcript
SurModics (SRDX) delivered earnings and revenue surprises of 110.00% and 8.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #FDAClearance--Surmodics receives FDA 510(k) clearance for Sublime™ Radial Access 0.014 RX PTA Dilatation Catheter.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports Third Quarter Fiscal 2020 Results and will hold a webcast conference call at 4 pm CT.
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics issues an earnings release after market closes and will host a webcast of fiscal 2020 third-quarter conference call on August 5 at 4 pm CT.
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for June 29th
Surmodics (SRDX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Top Ranked Momentum Stocks to Buy for June 26th 2020
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.
Surmodics' (SRDX) CEO Gary Maharaj on Q2 2020 Results - Earnings Call Transcript
SurModics (SRDX) delivered earnings and revenue surprises of 180.00% and 1.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
About SRDX
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologi... [Read more...]
| Industry Diagnostics & Research | IPO Date Mar 4, 1998 |
| CEO Gary Maharaj | Employees 370 |
| Stock Exchange NASDAQ | Ticker Symbol SRDX |
Financial Performance
In 2020, SurModics's revenue was $94.86 million, a decrease of -5.21% compared to the previous year's $100.08 million. Earnings were $1.12 million, a decrease of -85.21%.
Analyst Forecasts
According to 4 analysts, the average rating for SurModics stock is "Buy." The 12-month stock price forecast is 70.75, which is an increase of 21.58% from the latest price.